Labcorp (NYSE:LH) Director Sells $954,060.00 in Stock

Labcorp Holdings Inc. (NYSE:LH) Director Kerrii Anderson sold 3,000 shares of the business’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $318.02, for a total transaction of $954,060.00. Following the completion of the transaction, the director directly owned 6,563 shares of the company’s stock, valued at $2,087,165.26. The trade was a 31.37% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Labcorp Stock Up 1.6%

Shares of NYSE:LH opened at $323.18 on Tuesday. The stock’s 50-day moving average price is $287.48 and its two-hundred day moving average price is $275.09. The company has a current ratio of 1.80, a quick ratio of 1.53 and a debt-to-equity ratio of 0.69. Labcorp Holdings Inc. has a 12-month low of $244.52 and a 12-month high of $326.89. The firm has a market cap of $26.21 billion, a price-to-earnings ratio of 26.73, a PEG ratio of 1.84 and a beta of 0.87.

Labcorp (NYSE:LH) last released its quarterly earnings data on Thursday, July 30th. The medical research company reported $4.99 EPS for the quarter, topping analysts’ consensus estimates of $4.78 by $0.21. Labcorp had a return on equity of 16.74% and a net margin of 6.99%.The company had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.71 billion. During the same period last year, the business posted $4.35 EPS. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. On average, research analysts forecast that Labcorp Holdings Inc. will post 18.32 EPS for the current year.

Labcorp Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 28th will be paid a dividend of $0.72 per share. The ex-dividend date is Friday, August 28th. This represents a $2.88 annualized dividend and a yield of 0.9%. Labcorp’s payout ratio is presently 23.82%.

Institutional Investors Weigh In On Labcorp

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in shares of Labcorp by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 9,850,631 shares of the medical research company’s stock worth $2,471,326,000 after buying an additional 37,197 shares in the last quarter. Victory Capital Management Inc. raised its position in shares of Labcorp by 103.1% during the 4th quarter. Victory Capital Management Inc. now owns 5,356,825 shares of the medical research company’s stock valued at $1,343,922,000 after acquiring an additional 2,719,475 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in Labcorp by 1.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 2,226,446 shares of the medical research company’s stock valued at $607,241,000 after buying an additional 22,170 shares during the period. Geode Capital Management LLC raised its position in shares of Labcorp by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 2,137,010 shares of the medical research company’s stock valued at $534,023,000 after acquiring an additional 13,775 shares during the period. Finally, Wellington Management Group LLP raised its holdings in Labcorp by 15.9% in the third quarter. Wellington Management Group LLP now owns 2,105,791 shares of the medical research company’s stock worth $604,488,000 after purchasing an additional 289,029 shares during the period. Institutional investors own 95.94% of the company’s stock.

Wall Street Analyst Weigh In

LH has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $306.00 target price on shares of Labcorp in a research report on Friday, July 31st. Robert W. Baird set a $352.00 target price on shares of Labcorp in a report on Friday, July 31st. Weiss Ratings raised Labcorp from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, July 24th. Barclays raised their price objective on shares of Labcorp from $290.00 to $320.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 30th. Finally, Mizuho set a $355.00 target price on Labcorp in a research note on Monday, August 10th. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $330.00.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.